PTCH1
PTCH1 (patched 1, also known as PTCH, BCNS, NBCCS and SLC65B1) is the receptor for the secreted hedgehog morphogens and a negative regulator of smoothened signalling. It belongs to the patched family and has tumour suppressor properties. Browse Assay Genie's current range of PTCH1 research reagents below, or read on for the biology behind the target.
PTCH1 is a component of the hedgehog signalling pathway and acts as the receptor for the hedgehog ligands sonic hedgehog (SHH), indian hedgehog (IHH) and desert hedgehog (DHH). In the absence of ligand, it inhibits the G-protein-coupled receptor smoothened (SMO). It does this by acting as a cholesterol transporter. It depletes cholesterol from the outer leaflet of the plasma membrane, which prevents cholesterol binding to the extracellular CRD region of SMO.
When a hedgehog ligand binds, PTCH1 transporter activity is inhibited. SMO is then activated by cholesterol and downstream signalling proceeds. NCBI Gene notes that, after ligand binding, the protein is trafficked away from the primary cilium, which relieves inhibition of SMO. The molecular mechanism of cholesterol transport is still unclear. UniProt suggests that PTCH1 may move cholesterol from the outer to the inner leaflet of the membrane in exchange for potassium or sodium ion export in the opposite direction.
The PTCH1 protein is found in the cell membrane and the ciliary membrane. The PTCH1 gene is a member of the patched family. HGNC places it in solute carrier family 65, which explains the alias SLC65B1. Earlier names refer to the Drosophila patched homologue. Hedgehog signalling is important in embryonic development and tumorigenesis. Inactivation of PTCH1 is probably a necessary, if not sufficient, step for tumorigenesis. Mutations have been associated with basal cell nevus syndrome and holoprosencephaly.
PTCH1 is the receptor for SHH, IHH and DHH and restrains smoothened until ligand binding relieves that inhibition.
PTCH1 appears to act as a tumour suppressor, and its inactivation is probably a necessary step in tumorigenesis.
Hedgehog signalling is important in embryonic development, and PTCH1 mutations are associated with holoprosencephaly.
PTCH1 depletes membrane cholesterol to limit SMO activation and is trafficked away from the primary cilium after ligand binding.
PTCH1 is the receptor for sonic, indian and desert hedgehog. Without ligand it inhibits smoothened by acting as a cholesterol transporter that limits SMO access to cholesterol. Hedgehog binding inhibits this activity, which allows SMO activation and downstream signalling.
PTCH1 (patched 1) is also known as PTCH, BCNS, NBCCS and SLC65B1. Earlier names include patched homolog 1 (Drosophila). UniProt lists the protein as protein patched homolog 1, and HGNC places it in solute carrier family 65.
Mutations in PTCH1 have been associated with basal cell nevus syndrome and holoprosencephaly. It also seems to act as a tumour suppressor. The mouse ortholog is Ptch1; check the datasheet of any product for its validated reactivity.
Hedgehog ligands and the smoothened receptor that act alongside PTCH1 in the hedgehog signalling pathway.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q13635; product specifications from Assay Genie datasheets.